Biopharma Pulse - 1/24-1/28 Week in Review

As the last full week of January comes to a close, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.

Table 1. BPIQ company weekly moves and YTD moves

Highlights for the week of 1/24 - 1/28

Biggest positive move

SRRA up 56.9%; announced on Tuesday momelotinib MOMENTUM study achieved statistically significant benefit

Biggest negative move

EPZM down 48.3%; announced Thursday proposed public offering of common stock

Additional big moves

$OPK down 23%; received CRL

$TYME down 37.5%; discontinued trial arm

$EOLS up 17%; prelim Q4 2021 revenue

$CAPR up 21%; partnership with Nippon Shinyaku

$SLNO up 17%; additional DCCR study planned

$GLSI up 27%; implementation of stock repurchase program

$NVAX up 13.7%; Israel purchase agreement for COVID vaccine

Highlights for next week

$ETON PDUFA target action date

See our Big Movers post to learn about the remaining Jan Big Movers/Suspected Movers to watch